Simile has raised over $200 million at a $2 billion post-money valuation in a Series B led by Greenoaks, announced on 30 July 2026.
The round lands five months after a $100 million Series A led by Index Ventures, whose valuation was never disclosed, so the repricing cannot be measured.
CVS Health Ventures has invested in both rounds while CVS Health is named as a customer, and Deloitte, Gallup and Wealthfront are also listed as clients.
No revenue figure has been published. The company's fivefold growth claim is measured from an undisclosed base at a business that launched in February.
Read the full story on StartupFox